A 25-Year Experience of US Food and Drug Administration Accelerated Approval of Malignant Hematology and Oncology Drugs and Biologics: A Review

JAMA Oncology
Julia A BeaverPaul Kluetz

Abstract

Accelerated approval (AA) is a US Food and Drug Administration (FDA) expedited program intended to speed the approval of drugs and biologics that may demonstrate a meaningful advantage over available therapies for diseases that are serious or life-threatening. This review describes all malignant hematology and oncology AAs from inception of the program on December 11, 1992, to May 31, 2017. During this period, the FDA granted AA to 64 malignant hematology and oncology products for 93 new indications. Of these AAs, 53 were for new molecular entities. Overall, the end point of response rate, including hematologic response rates, accounted for most AAs (81 [87%]), followed by time-to-event end points of progression-free survival or time to progression (8 [9%]) and disease-free survival or recurrence-free survival (4 [4%]). Single-arm trial designs provided the data for 67 (72%) of the initial AA indications. Of the 93 AAs, 51 (55%) have fulfilled their postmarketing requirement and verified benefit in a median of 3.4 years after their initial AA. Thirty-seven (40%) indications have not yet completed confirmatory trial(s) or verified benefit, and 5 indications receiving AA (5%) have been withdrawn from the market. The use of the AA...Continue Reading

References

Mar 29, 2003·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·John R JohnsonRichard Pazdur
Oct 21, 2004·Journal of the National Cancer Institute·Ramzi DagherRichard Pazdur
Mar 23, 2011·Journal of the National Cancer Institute·John R JohnsonRichard Pazdur
Sep 14, 2011·Archives of Internal Medicine·Lisa M Schwartz, Steven Woloshin
Feb 26, 2016·JAMA Oncology·Gideon M Blumenthal, Richard Pazdur
Apr 27, 2016·JAMA : the Journal of the American Medical Association·Aaron S KesselheimLisa M Schwartz
Feb 6, 2017·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Paul G KluetzRichard Pazdur
Aug 16, 2017·JAMA : the Journal of the American Medical Association·Robert M Califf
Aug 16, 2017·JAMA : the Journal of the American Medical Association·Huseyin NaciAaron S Kesselheim

❮ Previous
Next ❯

Citations

Jun 7, 2018·Clinical Trials : Journal of the Society for Clinical Trials·Joshua D WallachHuseyin Naci
Sep 14, 2018·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Andrew D SeidmanLarissa A Korde
Sep 29, 2018·Pharmacoepidemiology and Drug Safety·Helen W SullivanNisha J Patel
Nov 21, 2018·JAMA : the Journal of the American Medical Association·Jeremy PuthumanaJoseph S Ross
Nov 28, 2018·Journal of Managed Care & Specialty Pharmacy·Daniel L ShawJoseph S Ross
Feb 12, 2019·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Scott F HuntingtonSapna A Prasad
Jan 14, 2019·Clinical Pharmacology and Therapeutics·Jessica M FranklinSebastian Schneeweiss
Feb 23, 2019·Journal of the National Comprehensive Cancer Network : JNCCN·Alyssa A SchatzRobert W Carlson
Mar 19, 2019·Clinical Pharmacology and Therapeutics·Sheng Liu, Aaron S Kesselheim
Jan 18, 2019·JAMA Oncology·Jessica K RoydhousePaul G Kluetz
Dec 19, 2018·Journal of the National Cancer Institute·Jessica K RoydhousePaul G Kluetz
Aug 8, 2018·Journal of the National Cancer Institute·Jiaxi ZhouRajeshwari Sridhara
May 18, 2019·American Society of Clinical Oncology Educational Book·Bishal GyawaliAriadna Tibau
May 6, 2019·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Ravi B Parikh, Vinay Prasad
Sep 29, 2019·The Journal of Law, Medicine & Ethics : a Journal of the American Society of Law, Medicine & Ethics·Audrey D Zhang, Joseph S Ross
Oct 2, 2019·The Milbank Quarterly·Brian J Miller, Gail Wilensky
Oct 12, 2018·Annals of Oncology : Official Journal of the European Society for Medical Oncology·C Wayant, M Vassar
Nov 30, 2019·Multiple Sclerosis : Clinical and Laboratory Research·Jeffrey A CohenRuth Ann Marrie
Nov 7, 2019·Therapeutic Innovation & Regulatory Science·Christina MackNancy Dreyer
Jan 15, 2020·JAMA : the Journal of the American Medical Association·Jonathan J DarrowAaron S Kesselheim
Jan 8, 2020·Clinical and Translational Science·Erica M CoxAishwarya Shankar
Jun 27, 2020·CPT: Pharmacometrics & Systems Pharmacology·Nidal Al-HunitiJennifer Sheng
Aug 18, 2020·The Oncologist·Helen W SullivanVanessa Boudewyns
Oct 3, 2018·Nature Reviews. Clinical Oncology·Sharyl J NassRichard L Schilsky
May 29, 2019·JAMA Internal Medicine·Bishal GyawaliAaron S Kesselheim
May 29, 2019·JAMA Internal Medicine·Sarah S P DiMagnoEzekiel J Emanuel
Apr 1, 2020·American Society of Clinical Oncology Educational Book·Andrew D SeidmanJulia A Beaver
Jul 5, 2018·Nature Reviews. Clinical Oncology·Bishal Gyawali, Aaron S Kesselheim
Jul 1, 2020·Therapeutic Innovation & Regulatory Science·Koji IrisawaMamoru Narukawa

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.

Related Papers

Journal of the National Comprehensive Cancer Network : JNCCN
Ann T Farrell, Richard Pazdur
Journal of the National Cancer Institute
Ramzi DagherRichard Pazdur
© 2022 Meta ULC. All rights reserved